Two staged phase II clinical trial of Eribulin monotherapy in advanced or recurrent cervical cancer

CONCLUSIONS: Eribulin shows modest activity in patients with recurrent/advanced cervical cancer with a favorable toxicity profile. Prior paclitaxel exposure is associated with decreased eribulin response. βII, βIII tubulin subtypes and BAX are predictors of response and survival. Eribulin may be an option for women with paclitaxel-naïve recurrent/advanced cervical cancer.PMID:37079977 | DOI:10.1016/j.ygyno.2023.02.016

Source: Gynecologic Oncology - April 18, 2023 Category: Cancer & Oncology Authors: Jocelyn Garcia-Sayre Yvonne G Lin Koji Matuso Denice D Tsao-Wei Paulette Mhawech-Fauceglia Stan Louie Tiange Dong Marcia A Ciccone Laurie L Brunette-Masi Huyen Q Pham Annie A Yessaian Susan G Groshen Grace Facio Marissa Aldana Laila I Muderspach Agustin A Source Type: research